Federal contract award
75F40123F19054
FY2023 STREAMLINE PROCESSES AND ENHANCE NEW DRUG REVIEW
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541611 — Administrative Management and General Management Consulting Services |
| PSC | R406 — Policy Review/Development Services |
| Parent award / vehicle | 75F40122A00009 |
| Set-aside | Not reported |
| Pricing type | LABOR HOURS |
| Obligations | $2.0M |
| Current contract value | $2.0M |
| Potential contract value / ceiling | $2.0M |
| Start date | Feb 16, 2023 |
| Current end date | Jun 13, 2025 |
| Potential end date | Jun 13, 2025 |
| Latest award activity | Aug 5, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 5, 2026 | P00005 | $-17.2K | FY2023 STREAMLINE PROCESSES AND ENHANCE NEW DRUG REVIEW - FY26 UDO INIATIVE |
| Jun 13, 2025 | P00004 | $0 | FY2023 STREAMLINE PROCESSES AND ENHANCE NEW DRUG REVIEW |
| Nov 1, 2024 | P00003 | $0 | FY2023 STREAMLINE PROCESSES AND ENHANCE NEW DRUG REVIEW |
| Jun 11, 2024 | P00002 | $0 | FY2023 STREAMLINE PROCESSES AND ENHANCE NEW DRUG REVIEW |
| Jan 30, 2024 | P00001 | $1.2M | FY2023 STREAMLINE PROCESSES AND ENHANCE NEW DRUG REVIEW |
| Feb 16, 2023 | 0 | $800.2K | FY2023 STREAMLINE PROCESSES AND ENHANCE NEW DRUG REVIEW |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.